KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Fulgent Genetics (FLGT) EBIAT (2016 - 2026)

Fulgent Genetics' EBIAT history spans 12 years, with the latest figure at -$24.8 million for Q1 2026.

  • On a quarterly basis, EBIAT fell 108.64% to -$24.8 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$74.3 million, a 77.7% decrease, with the full-year FY2025 number at -$60.5 million, down 38.09% from a year prior.
  • EBIAT hit -$24.8 million in Q1 2026 for Fulgent Genetics, down from -$23.4 million in the prior quarter.
  • Over the last five years, EBIAT for FLGT hit a ceiling of $153.6 million in Q1 2022 and a floor of -$134.3 million in Q4 2023.
  • Historically, EBIAT has averaged -$9.6 million across 5 years, with a median of -$13.1 million in 2023.
  • Biggest five-year swings in EBIAT: tumbled 862.48% in 2023 and later soared 95.39% in 2024.
  • Tracing FLGT's EBIAT over 5 years: stood at -$24.1 million in 2022, then plummeted by 457.96% to -$134.3 million in 2023, then soared by 95.39% to -$6.2 million in 2024, then tumbled by 278.32% to -$23.4 million in 2025, then decreased by 6.01% to -$24.8 million in 2026.
  • Business Quant data shows EBIAT for FLGT at -$24.8 million in Q1 2026, -$23.4 million in Q4 2025, and -$6.8 million in Q3 2025.